Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients withSLAM-Associated Protein Deficiency/X-linked Lymphoproliferative Disease Type 1

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 10, 2014, Pages 1641-1645

  Marsh, Rebecca A ^a   Bleesing, Jack J ^a   Chandrakasan, Shanmuganathan ^a   Jordan, Michael B ^a   Davies, Stella M ^a   Filipovich, Alexandra H ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Alemtuzumab; Allogeneic hematopoietic cell transplant; Bone marrow transplant; Reduced intensity conditioning; SH2D1A; SLAM associated protein; X linked lymphoproliferative disease; XLP

Indexed keywords

ALEMTUZUMAB; CIDOFOVIR; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYELOABLATIVE AGENT; SH2D1A PROTEIN, HUMAN; SIGNAL PEPTIDE; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE KIDNEY FAILURE; ADOLESCENT; ARTICLE; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DONOR; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; ENCEPHALITIS; EPSTEIN BARR VIRUS INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HERPES VIRUS INFECTION; HLA SYSTEM; HUMAN; HUMAN HERPESVIRUS 6 INFECTION; IMMUNOGLOBULIN DEFICIENCY; INFECTIOUS COMPLICATION; INTERSTITIAL PNEUMONIA; LIVER VEIN OBSTRUCTION; LONG TERM SURVIVAL; LUNG HEMORRHAGE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE ACTIVATION SYNDROME; PHENOTYPE; PRESCHOOL CHILD; PROTEIN DEFICIENCY; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SCHOOL CHILD; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN DEFICIENCY; STEM CELL; SURVIVAL; SURVIVAL RATE; VIREMIA; VIRUS REACTIVATION; X LINKED LYMPHOPROLIFERATIVE DISEASE TYPE 1; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; FEMALE; GENETICS; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MORTALITY; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; UNRELATED DONORS;

ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MELPHALAN; MUTATION; MYELOABLATIVE AGONISTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; VIDARABINE;

EID: 84912521411     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.06.003     Document Type: Article

References (15)

1. Sayos J., Wu C., Morra M., et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998, 395:462-469.
2. Coffey A.J., Brooksbank R.A., Brandau O., et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998, 20:129-135.
3. Nichols K.E., Harkin D.P., Levitz S., et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA 1998, 95:13765-13770.
4. Seemayer T.A., Gross T.G., Egeler R.M., et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 1995, 38:471-478.
5. Pachlopnik Schmid J., Canioni D., Moshous D., et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011, 117:1522-1529.
6. Kanegane H., Yang X., Zhao M., et al. Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis. Pediatr Allergy Immunol 2012, 23:488-493.
7. Booth C., Gilmour K.C., Veys P., et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 2011, 117:53-62.
8. Lankester A.C., Visser L.F., Hartwig N.G., et al. Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature. Bone Marrow Transplant 2005, 36:99-105.
9. Marsh R.A., Vaughn G., Kim M.O., et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 2010, 116:5824-5831.
10. Cooper N., Rao K., Gilmour K., et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006, 107:1233-1236.
11. Cooper N., Rao K., Goulden N., et al. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant 2008, 42(Suppl. 2):S47-S50.
12. Marsh R.A., Kim M.O., Liu C., et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant 2013, 19:1625-1631.
13. Shenoy S., Grossman W.J., DiPersio J., et al. Anovel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 2005, 35:345-352.
14. Karnofsky D., Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of chemotherapeutic agents 1949, 196. Columbia University Press, New York. C.M. MacLeod (Ed.).
15. Lansky S.B., List M.A., Lansky L.L., et al. The measurement of performance in childhood cancer patients. Cancer 1987, 60:1651-1656.